DrugPatentWatch Database Preview
XURIDEN Drug Profile
see a sample report or, see our see our flat-rate plans
When do Xuriden patents expire, and what generic alternatives are available?
Xuriden is a drug marketed by Wellstat Therap and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in XURIDEN is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.
Summary for XURIDEN
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 51 |
| Patent Applications: | 39 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | XURIDEN at DailyMed |
Pharmacology for XURIDEN
| Ingredient-type | Pyrimidines Analogs/Derivatives |
| Drug Class | Pyrimidine Analog |
Synonyms for XURIDEN
| (2R,3R,4R,5R)-2-(ACETOXYMETHYL)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)TETRAHYDROFURAN-3,4-DIYL DIACETATE |
| [(2R,3R,4R,5R)-3,4-diacetoxy-5-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-2-yl]methyl acetate |
| [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate |
| 105T388 |
| 2 ,3 ,5 -Triacetyluridine |
| 2',3',5'-Tri-O-acetyluridine |
| 293738-13-3 |
| 2WP61F175M |
| 4105-38-8 |
| AC1L2FGB |
| AK-73070 |
| AKOS015964563 |
| AN-158 |
| ANW-29551 |
| API0001026 |
| AUFUWRKPQLGTGF-FMKGYKFTSA-N |
| AX8007900 |
| CHEBI:90914 |
| CHEMBL2107381 |
| CTK3J5861 |
| D09985 |
| D0OL7F |
| DB09144 |
| EINECS 223-881-5 |
| FT-0081134 |
| J-700012 |
| KSC495Q6D |
| MFCD00023795 |
| MLS006009982 |
| MolPort-005-940-324 |
| NU000494 |
| PN 401 |
| PN401 |
| PubChem14176 |
| RG 2133 |
| SCHEMBL871011 |
| SMR004701034 |
| SY004945 |
| Tri-O-acetyluridine |
| Triacetyluridine |
| UNII-2WP61F175M |
| URI007 |
| Uridine 2',3',5'-triacetate |
| Uridine triacetate |
| Uridine triacetate (USAN/INN) |
| Uridine triacetate [USAN:INN] |
| Uridine, 2',3',5'-triacetate |
| Vistonuridine |
| Xuriden (TN) |
| ZINC3843198 |
US Patents and Regulatory Information for XURIDEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for XURIDEN
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,060,459 | Enhancing blood cell count with oxypurine nucleosides | ➤ Sign Up |
| 6,329,350 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | ➤ Sign Up |
| 6,103,701 | Method for enhancing hematopoiesis with acyl deoxyribonucleosides | ➤ Sign Up |
| 6,306,834 | Acyl deoxyribonucleoside derivatives and uses thereof | ➤ Sign Up |
| 5,246,708 | Methods for promoting wound healing with deoxyribonucleosides | ➤ Sign Up |
| 5,736,531 | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for XURIDEN
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | H02500373 | ➤ Sign Up |
| Canada | 2150940 | ➤ Sign Up |
| Norway | 904611 | ➤ Sign Up |
| South Africa | 8808083 | ➤ Sign Up |
| Australia | 2722688 | ➤ Sign Up |
| Israel | 88204 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for XURIDEN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017 00036 | Denmark | ➤ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427 |
| 0889 | Netherlands | ➤ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
